HR and breast cancer: Notably, a novel TROP2-targeted ADC (20), datopotamab deruxtecan (Dato-DXd) demonstrated promising clinical activity (ORR = 26.8% in HR+/HER2- BC; ORR = 31.8% in TNBC) and a manageable safety profile (stomatitis being the most common adverse event) in heavily pretreated patients with advanced HR+/HER2- breast cancer or triple-negative breast cancer, and is currently under evaluation in phase III studies (21).